Cargando…

Effectiveness and Safety of Switching Rapid-Acting Insulins to Insulin Glulisine in Patients with Diabetes: The Observational IGLU-S Study

INTRODUCTION: The IGLU-S study assessed the effectiveness of insulin glulisine after switching from human insulin/other rapid-acting insulin analogues in patients with type 1 diabetes (T1DM) and type 2 diabetes (T2DM) in a real-world setting in Germany. METHODS: Open-label, prospective, multicentre,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seufert, Jochen, Pfohl, Martin, Borck, Anja, Bramlage, Peter, Siegmund, Thorsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947079/ https://www.ncbi.nlm.nih.gov/pubmed/33544356 http://dx.doi.org/10.1007/s13300-021-00999-y

Ejemplares similares

Effectiveness and Safety of Insulin Glulisine When Initiating Supplementary Prandial Insulin Treatment (SIT) in Insulin-Naïve Patients with Type 2 Diabetes: The Observational IGLU-SIT Study
por: Pfohl, Martin, et al.
Publicado: (2021)

Effectiveness and tolerability of treatment intensification to basal–bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study
por: Pfohl, Martin, et al.
Publicado: (2015)

Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen
por: Seufert, Jochen, et al.
Publicado: (2019)

Efficacy and safety of switching to insulin glulisine from other rapid-acting insulin analogs in children with type 1 diabetes
por: Urakami, Tatsuhiko, et al.
Publicado: (2015)

Insulin glulisine in the management of diabetes
por: Yamada, Satoru
Publicado: (2009)

A Difference Between Bedtime and Pre-Breakfast Plasma Glucose Levels Indicates the Need for Prandial Insulin in Basal Insulin-Treated Type 2 Diabetic Patients with Normal Fasting Glucose
por: Kress, Stephan, et al.
Publicado: (2021)

Immunologic Tolerance to the Insulin Analogue Glulisine
por: Ozaki, Nobuaki, et al.
Publicado: (2010)

HbA1c target achievement in the elderly: results of the Titration and Optimization trial for initiation of insulin glargine 100 U/mL in patients with type 2 diabetes poorly controlled on oral antidiabetic drugs
por: Fritsche, Andreas, et al.
Publicado: (2019)

Iglú : de arquitectura vernácula a contemporánea /
Publicado: (2008)

A higher blood glucose level pre-breakfast in comparison to bedtime is a contraindication for intensification of prandial insulin therapy in patients with type 2 diabetes – The impact of a negative BeAM value
por: Siegmund, Thorsten, et al.
Publicado: (2018)

A case of type 1 diabetes mellitus with which localized insulin allergy was markedly alleviated by switching to insulin glulisine
por: Watanabe, Kahori, et al.
Publicado: (2016)

The role of insulin glulisine to improve glycemic control in children with diabetes mellitus
por: Lih, Anna, et al.
Publicado: (2010)

Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study
por: Seufert, Jochen, et al.
Publicado: (2013)

Treatment intensification using long-acting insulin –predictors of future basal insulin supported oral therapy in the DIVE registry
por: Danne, Thomas, et al.
Publicado: (2015)

Combining insulins for optimal blood glucose control in type 1 and 2 diabetes: Focus on insulin glulisine
por: Ulrich, Heather, et al.
Publicado: (2007)

Insulin Glulisine May Cause a Disease Resembling Insulin Autoimmune Syndrome: Case Report
por: Kawasaki, Maki, et al.
Publicado: (2013)

Diabetic Ketosis Caused by the Insulin Analog Aspart–Induced Anti-Insulin Antibody: Successful Treatment With the Newest Insulin Analog Glulisine
por: Yanai, Hidekatsu, et al.
Publicado: (2011)

Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update
por: Hanefeld, Markolf, et al.
Publicado: (2020)

Effectiveness and safety of insulin glargine 300 U/mL in insulin‐naïve patients with type 2 diabetes after failure of oral therapy in a real‐world setting
por: Pfohl, Martin, et al.
Publicado: (2020)

Insulin Glulisine in Pregnancy – Experience from Clinical Trials and Post-marketing Surveillance
por: Doder, Zoran, et al.
Publicado: (2015)

Analysis of insulin glulisine at the molecular level by X-ray crystallography and biophysical techniques
por: Gillis, Richard B., et al.
Publicado: (2021)

Interpreting blood GLUcose data with R package iglu
por: Broll, Steven, et al.
Publicado: (2021)

Comparison of the efficacy and safety of insulin degludec/aspart (twice‐daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal–bolus therapy)
por: Kawaguchi, Yuji, et al.
Publicado: (2019)

Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes
por: Bolli, G B, et al.
Publicado: (2011)

Pharmacokinetics and pharmacodynamics of insulin glargine–insulin glulisine basal-bolus and twice-daily premixed analog insulin in type 1 diabetes mellitus patients during three standardized meals
por: Lamos, Elizabeth Mary, et al.
Publicado: (2015)

Metabolic and sympathovagal effects of bolus insulin glulisine versus basal insulin glargine therapy in people with type 2 diabetes: A randomized controlled study
por: Takeshita, Yumie, et al.
Publicado: (2020)

Adjust to Target in Type 2 Diabetes: Comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine
por: Bergenstal, Richard M., et al.
Publicado: (2008)

Comparisons of efficacy and safety in insulin glargine and lixisenatide plus glulisine combination therapy with multiple daily injection therapy in Japanese patients with type 2 diabetes
por: Kawaguchi, Yuji, et al.
Publicado: (2021)

PSUN227 A retrospective comparison of Basal Bolus using Glargine U-300 and Glulisine with Premix Insulin
por: Abraham, Santhosh, et al.
Publicado: (2022)

Insulin Glargine 300 U/mL and Insulin Glulisine Treatment in Patients with Type 2 Diabetes: A Non-Interventional Study of Effectiveness in Routine Clinical Practice
por: Hidvégi, Tibor, et al.
Publicado: (2020)

Comparison of morning basal + 1 bolus insulin therapy (insulin glulisine + insulin glargine 300 U/mL vs insulin lispro + insulin glargine biosimilar) using continuous glucose monitoring: A randomized crossover study
por: Takeishi, Soichi, et al.
Publicado: (2017)

A Randomized Trial of Two Weight-Based Doses of Insulin Glargine and Glulisine in Hospitalized Subjects With Type 2 Diabetes and Renal Insufficiency
por: Baldwin, David, et al.
Publicado: (2012)

Real world outcomes of adding rapid-acting insulin versus switching to analog premix insulin among US patients with type 2 diabetes treated with insulin glargine
por: Miao, Raymond, et al.
Publicado: (2013)

Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month ‘proof-of-concept’ study
por: Owens, D R, et al.
Publicado: (2011)

Real-world efficacy and safety of insulin degludec with mealtime rapid-acting insulin in type 1 diabetes in Indian pediatric population
por: Kochar, Inderpal Singh, et al.
Publicado: (2018)

Glulisine Versus Human Regular Insulin in Combination With Glargine in Noncritically Ill Hospitalized Patients With Type 2 Diabetes: A randomized double-blind study
por: Meyer, Christian, et al.
Publicado: (2010)

SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
por: Seufert, Jochen
Publicado: (2015)

Optimizing Insulin Glargine Plus One Injection of Insulin Glulisine in Type 2 Diabetes in the ELEONOR Study: Similar effects of telecare and conventional self-monitoring of blood glucose on patient functional health status and treatment satisfaction
por: Nicolucci, Antonio, et al.
Publicado: (2011)

A European, multicentre, retrospective, non‐interventional study (EU‐TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes
por: Siegmund, Thorsten, et al.
Publicado: (2017)

Rapid-Acting and Human Insulins: Hexamer Dissociation Kinetics upon Dilution of the Pharmaceutical Formulation
por: Gast, Klaus, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2bmmeprs4mpivjigpv7i4os8ai